Pipeline products
Our next generation, programmed T cell therapies in development
Treating hematological malignancies and solid tumors
The company has an approved product for the treatment of r/r adult ALL, which is approved by the FDA and is also under review in the UK and Europe.
The opportunity extends beyond adult ALL. Obe-cel is currently being investigated in ongoing clinical studies for B-NHL, pediatric ALL and systemic lupus erythematosus (SLE). Alongside obe-cel, Autolus is progressing a number of pipeline assets both in preclinical and clinical development across hematological malignancies and solid tumors.
Our pipeline
Our products
Autolus are applying our extensive cell programming capability to develop product candidates across hematological malignancies and solid tumors as well as autoimmune diseases
Read more